# A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

> **NCT05712278** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 7 (actual)

## Conditions studied

- Acute Myeloid Leukaemia

## Interventions

- **DRUG:** SAR445419
- **DRUG:** fludarabine
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT05712278
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-16
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-03-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712278, "A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05712278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*